CoChat
Sign Up
Cited by 494

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: Selective targeting to diseased versus healthy tissue

Hua, Susan, Marks, Ellen, Schneider, Jennifer J., Keely, Simon·2015·Nanomedicine: Nanotechnology, Biology and Medicine
DOI 10.1016/j.nano.2015.02.018
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nano.2015.02.018

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Physiological and microbial changes to the GI tract in inflammatory bowel disease. IBD patients have increased orocecal transit times in the absence of small intestinal bacterial overgrowth (SIBO). 39 Tissue resection 59 or SIBO 39 can significantly reduce transit time. IBD patients exhibit minor elevation in small intestinal pH, 45,46 however there are significant decreases seen in the colonic pH of both CD and UC patients. 21,47 These changes in pH and motility may facilitate the widespread changes in commensal populations in the GI tract, affecting the small intestine and the colon. 29,42
Figure 1 Physiological and microbial changes to the GI tract in inflammatory bowel disease. IBD patients have increased orocecal transit times in the absence of small intestinal bacterial overgrowth (SIBO). 39 Tissue resection 59 or SIBO 39 can significantly reduce transit time. IBD patients exhibit minor elevation in small intestinal pH, 45,46 however there are significant decreases seen in the colonic pH of both CD and UC patients. 21,47 These changes in pH and motility may facilitate the widespread changes in commensal populations in the GI tract, affecting the small intestine and the colon. 29,42CC-BY-NC-ND · From the PDF
Figure 2 Characteristic changes to the mucosal barrier in inflammatory bowel disease. The healthy mucosa (A) is protected by an inner adherent and outer mobile mucous-gel layer, which acts as a barrier to large molecules and hydrophobic compounds. 28 Underneath the mucous layer, a selectively permeable epithelial barrier allows nutrient absorption while excluding bacteria and luminal contents from the serosa. Antigen sampling is performed by Microfold (M) cells overlying lymphoid follicles. These M cells have a reduced or absent mucous-gel layer, 28 and may be targeted by nanoparticles. 72,73 Mucosal inflammation (B) is associated with a loss of both the inner adherent and outer mobile mucous-gel layers, loss of epithelial barrier integrity through enterocyte damage, and increased translocation of intestinal bacteria leading to a recruitment of immune cells to the mucosal tissue. These changes lead to a preferential accumulation and uptake of nanoparticles by both enterocytes and macrophages, including increased exposure of inflammatory receptor targets to nanoparticles.
Figure 2 Characteristic changes to the mucosal barrier in inflammatory bowel disease. The healthy mucosa (A) is protected by an inner adherent and outer mobile mucous-gel layer, which acts as a barrier to large molecules and hydrophobic compounds. 28 Underneath the mucous layer, a selectively permeable epithelial barrier allows nutrient absorption while excluding bacteria and luminal contents from the serosa. Antigen sampling is performed by Microfold (M) cells overlying lymphoid follicles. These M cells have a reduced or absent mucous-gel layer, 28 and may be targeted by nanoparticles. 72,73 Mucosal inflammation (B) is associated with a loss of both the inner adherent and outer mobile mucous-gel layers, loss of epithelial barrier integrity through enterocyte damage, and increased translocation of intestinal bacteria leading to a recruitment of immune cells to the mucosal tissue. These changes lead to a preferential accumulation and uptake of nanoparticles by both enterocytes and macrophages, including increased exposure of inflammatory receptor targets to nanoparticles.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 146

  1. Podolsky, 2002, Inflammatory bowel disease, N Engl J Med, 347, 417, 10.1056/NEJMra020831 · DOI
  2. Sartor, 2010, Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis, Gastroenterology, 139, 1816, 10.1053/j.gastro.2010.10.036 · DOI · Paper page
  3. Keely, 2009, Dexamethasone–pDMAEMA polymeric conjugates reduce inflammatory biomarkers in human intestinal epithelial monolayers, J Control Release, 135, 35, 10.1016/j.jconrel.2008.12.001 · DOI
  4. Podolsky, 2003, The future of IBD treatment, J Gastroenterol, 38, 63
  5. Talley, 2011, An evidence-based systematic review on medical therapies for inflammatory bowel disease, Am J Gastroenterol, 106, S2, 10.1038/ajg.2011.58 · DOI
  6. Byrne, 2007, Patient preferences between surgical and medical treatment in Crohn's disease, Dis Colon Rectum, 50, 586, 10.1007/s10350-006-0847-0 · DOI
  7. Yang, 2002, Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation, Int J Pharm, 235, 1, 10.1016/S0378-5173(02)00004-2 · DOI
  8. Sandborn, 2002, Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis, Am J Gastroenterol, 97, 2939, 10.1111/j.1572-0241.2002.07092.x · DOI
  9. Hanauer, 2004, COLAL-PRED Alizyme, Curr Opin Investig Drugs, 5, 1192
  10. Steed, 1997, The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system (“TIME CLOCK (R)” system), J Control Release, 49, 115, 10.1016/S0168-3659(97)00062-X · DOI
  11. Hebden, 2000, Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis, Aliment Pharmacol Ther, 14, 155, 10.1046/j.1365-2036.2000.00697.x · DOI
  12. Hua, 2014, Orally administered liposomal formulations for colon targeted drug delivery, Front Pharmacol, 5, 1, 10.3389/fphar.2014.00138 · DOI
  13. Laroui, 2010, Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model, Gastroenterology, 138, 843, 10.1053/j.gastro.2009.11.003 · DOI
  14. Coco, 2013, Drug delivery to inflamed colon by nanoparticles: comparison of different strategies, Int J Pharm, 440, 3, 10.1016/j.ijpharm.2012.07.017 · DOI · Paper page
  15. Asghar, 2006, Multiparticulate formulation approach to colon specific drug delivery: current perspectives, J Pharm Pharm Sci, 9, 327
  16. Hu, 2000, Application of a biomagnetic measurement system (BMS) to the evaluation of gastrointestinal transit of intestinal pressure-controlled colon delivery capsules (PCDCs) in human subjects, Pharm Res, 17, 160, 10.1023/A:1007561129221 · DOI · Paper page
  17. Coupe, 1991, Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects, Pharm Res, 8, 360, 10.1023/A:1015849700421 · DOI · Paper page
  18. Rao, 2004, Objective evaluation of small bowel and colonic transit time using pH telemetry in athletes with gastrointestinal symptoms, Br J Sports Med, 38, 482, 10.1136/bjsm.2003.006825 · DOI · Paper page
  19. Buhmann, 2007, Assessment of colonic transit time using MRI: a feasibility study, Eur Radiol, 17, 669, 10.1007/s00330-006-0414-z · DOI · Paper page
  20. Sathyan, 2000, Effect of dosing time on the total intestinal transit time of non-disintegrating systems, Int J Pharm, 204, 47, 10.1016/S0378-5173(00)00472-5 · DOI
  21. Fallingborg, 1993, Very low intraluminal colonic pH in patients with active ulcerative colitis, Dig Dis Sci, 38, 1989, 10.1007/BF01297074 · DOI
  22. Bratten, 2006, New directions in the assessment of gastric function: clinical applications of physiologic measurements, Dig Dis, 24, 252, 10.1159/000092878 · DOI · Paper page
  23. Nugent, 2001, Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs, Gut, 48, 571, 10.1136/gut.48.4.571 · DOI
  24. Sasaki, 1997, Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn's disease, Am J Gastroenterol, 92, 114
  25. Ibekwe, 2008, Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems, Pharm Res, 25, 1828, 10.1007/s11095-008-9580-9 · DOI · Paper page
  26. Nyhof, 1985, Effect of atropine on digested food-induced intestinal hyperemia, Am J Physiol, 249, G685
  27. Fatouros, 2008, In vitro lipid digestion models in design of drug delivery systems for enhancing oral bioavailability, Expert Opin Drug Metab Toxicol, 4, 65, 10.1517/17425255.4.1.65 · DOI
  28. Keely, 2011, Chloride-led disruption of the intestinal mucous layer impedes Salmonella invasion: evidence for an ‘enteric tear’ mechanism, Cell Physiol Biochem, 28, 743, 10.1159/000335768 · DOI
  29. Sartor, 2008, Microbial influences in inflammatory bowel diseases, Gastroenterology, 134, 577, 10.1053/j.gastro.2007.11.059 · DOI · Paper page
  30. Macfarlane, 2011, Fermentation in the human large intestine: its physiologic consequences and the potential contribution of prebiotics, J Clin Gastroenterol, 45, S120, 10.1097/MCG.0b013e31822fecfe · DOI · Paper page
  31. Sinha, 2001, Polysaccharides in colon-specific drug delivery, Int J Pharm, 224, 19, 10.1016/S0378-5173(01)00720-7 · DOI · Paper page
  32. Frank, 2007, Molecular–phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases, Proc Natl Acad Sci U S A, 104, 13780, 10.1073/pnas.0706625104 · DOI · Paper page
  33. Britton, 2014, Role of the intestinal microbiota in resistance to colonization by Clostridium difficile, Gastroenterology, 146, 1547, 10.1053/j.gastro.2014.01.059 · DOI · Paper page
  34. Patel, 2014, Mucosal inflammatory response to Salmonella typhimurium infection, Front Immunol, 5, 311, 10.3389/fimmu.2014.00311 · DOI
  35. Grover, 2008, Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress, Neurogastroenterol Motil, 20, 998, 10.1111/j.1365-2982.2008.01142.x · DOI · Paper page
  36. Li, 2003, Basement membrane components, J Clin Pathol, 56, 885, 10.1136/jcp.56.12.885 · DOI
  37. Antoni, 2014, Intestinal barrier in inflammatory bowel disease, World J Gastroenterol, 20, 1165, 10.3748/wjg.v20.i5.1165 · DOI
  38. Rana, 2013, Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease, Dig Dis Sci, 58, 2594, 10.1007/s10620-013-2694-x · DOI
  39. Kashyap, 2013, Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice, Gastroenterology, 144, 967, 10.1053/j.gastro.2013.01.047 · DOI · Paper page
  40. Sartor, 2008, Therapeutic correction of bacterial dysbiosis discovered by molecular techniques, Proc Natl Acad Sci U S A, 105, 16413, 10.1073/pnas.0809363105 · DOI
  41. Linskens, 2001, The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics, Scand J Gastroenterol Suppl, 234, 29, 10.1080/003655201753265082 · DOI · Paper page
  42. Keely, 2012, Activated fluid transport regulates bacterial–epithelial interactions and significantly shifts the murine colonic microbiome, Gut Microbes, 3, 250, 10.4161/gmic.20529 · DOI
  43. Musch, 2013, Lubiprostone decreases mouse colonic inner mucus layer thickness and alters intestinal microbiota, Dig Dis Sci, 58, 668, 10.1007/s10620-012-2509-5 · DOI
  44. Barkas, 2013, Electrolyte and acid–base disorders in inflammatory bowel disease, Ann Gastroenterol, 26, 23
  45. Lucas, 1978, Acid microclimate in coeliac and Crohn's disease: a model for folate malabsorption, Gut, 19, 735, 10.1136/gut.19.8.735 · DOI
  46. McConnell, 2008, Gut instincts: explorations in intestinal physiology and drug delivery, Int J Pharm, 364, 213, 10.1016/j.ijpharm.2008.05.012 · DOI
  47. Van Citters, 2006, Ileal brake: neuropeptidergic control of intestinal transit, Curr Gastroenterol Rep, 8, 367, 10.1007/s11894-006-0021-9 · DOI · Paper page
  48. Yang, 2008, Biorelevant dissolution testing of colon-specific delivery systems activated by colonic microflora, J Control Release, 125, 77, 10.1016/j.jconrel.2007.10.026 · DOI · Paper page
  49. Laukoetter, 2008, Role of the intestinal barrier in inflammatory bowel disease, World J Gastroenterol, 14, 401, 10.3748/wjg.14.401 · DOI
  50. Cunningham, 2012, Myosin light chain kinase: pulling the strings of epithelial tight junction function, Ann N Y Acad Sci, 1258, 34, 10.1111/j.1749-6632.2012.06526.x · DOI · Paper page
  51. Wang, 2010, Restoration of rat colonic epithelium after in situ intestinal instillation of the absorption promoter, sodium caprate, Ther Deliv, 1, 75, 10.4155/tde.10.5 · DOI
  52. Goggins, 2013, Hypoxia and integrin-mediated epithelial restitution during mucosal inflammation, Front Immunol, 4, 272, 10.3389/fimmu.2013.00272 · DOI
  53. Comerford, 2002, Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene, Cancer Res, 62, 3387
  54. Creed, 2007, Review article: steroid resistance in inflammatory bowel disease—mechanisms and therapeutic strategies, Aliment Pharmacol Ther, 25, 111, 10.1111/j.1365-2036.2006.03156.x · DOI
  55. Dong, 2009, Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP, Cancer Res, 69, 3918, 10.1158/0008-5472.CAN-08-2747 · DOI
  56. Schmidt, 1996, Effect of intestinal resection on human small bowel motility, Gut, 38, 859, 10.1136/gut.38.6.859 · DOI
  57. Spiller, 1988, Further characterisation of the ‘ileal brake’ reflex in man—effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY, Gut, 29, 1042, 10.1136/gut.29.8.1042 · DOI
  58. Fallingborg, 1998, Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease, Dig Dis Sci, 43, 702, 10.1023/A:1018893409596 · DOI
  59. Gracie, 2012, Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea, Neurogastroenterol Motil, 24, 983-e538, 10.1111/j.1365-2982.2012.01953.x · DOI
  60. Thompson, 1998, Role of the ileocecal junction in the motor response to intestinal resection, J Gastrointest Surg, 2, 174, 10.1016/S1091-255X(98)80010-3 · DOI
  61. Ammon, 1974, Inhibition of ileal water absorption by intraluminal fatty acids. Influence of chain length, hydroxylation, and conjugation of fatty acids, J Clin Invest, 53, 205, 10.1172/JCI107539 · DOI
  62. Watts, 1992, The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis, Int J Pharm, 87, 215, 10.1016/0378-5173(92)90245-W · DOI
  63. Van Citters, 1999, The ileal brake: a fifteen-year progress report, Curr Gastroenterol Rep, 1, 404, 10.1007/s11894-999-0022-6 · DOI
  64. Lin, 2005, Measurement of gastrointestinal transit, Dig Dis Sci, 50, 989, 10.1007/s10620-005-2694-6 · DOI
  65. Malayandi, 2014, Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease, Drug Deliv Transl Res, 4, 187, 10.1007/s13346-013-0185-4 · DOI
  66. Xiao, 2012, Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease, Expert Opin Drug Deliv, 9, 1393, 10.1517/17425247.2012.730517 · DOI · Paper page
  67. Collnot, 2012, Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa, J Control Release, 161, 235, 10.1016/j.jconrel.2012.01.028 · DOI
  68. Lamprecht, 2005, Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats, J Pharmacol Exp Ther, 315, 196, 10.1124/jpet.105.088146 · DOI
  69. Beloqui, 2013, Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis, Int J Pharm, 454, 775, 10.1016/j.ijpharm.2013.05.017 · DOI
  70. Hillyer, 2001, Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles, J Pharm Sci, 90, 1927, 10.1002/jps.1143 · DOI
  71. des Rieux, 2005, Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium, Eur J Pharm Sci, 25, 455, 10.1016/j.ejps.2005.04.015 · DOI
  72. Pichai, 2012, Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases, World J Gastroenterol, 18, 2895, 10.3748/wjg.v18.i23.2895 · DOI
  73. Lamprecht, 2001, Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa, Pharm Res, 18, 788, 10.1023/A:1011032328064 · DOI · Paper page
  74. Lamprecht, 2010, IBD: selective nanoparticle adhesion can enhance colitis therapy, Nat Rev Gastroenterol Hepatol, 7, 311, 10.1038/nrgastro.2010.66 · DOI
  75. Wachsmann, 2013, Surfactant-dependence of nanoparticle treatment in murine experimental colitis, J Control Release, 172, 62, 10.1016/j.jconrel.2013.07.031 · DOI
  76. Schmidt, 2013, Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients, J Control Release, 165, 139, 10.1016/j.jconrel.2012.10.019 · DOI
  77. Han, 2012, Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system, Eur J Pharm Sci, 46, 500, 10.1016/j.ejps.2012.04.002 · DOI
  78. Liu, 2005, Interaction of various pectin formulations with porcine colonic tissues, Biomaterials, 26, 5907, 10.1016/j.biomaterials.2005.03.005 · DOI
  79. Larsson, 2009, A complex, but uniform O-glycosylation of the human MUC2 mucin from colonic biopsies analyzed by nanoLC/MSn, Glycobiology, 19, 756, 10.1093/glycob/cwp048 · DOI
  80. Urayama, 1997, Mechanisms and treatment of diarrhea in inflammatory bowel diseases, Inflamm Bowel Dis, 3, 114, 10.1097/00054725-199706000-00006 · DOI
  81. Niebel, 2012, Nanoparticle-based clodronate delivery mitigates murine experimental colitis, J Control Release, 160, 659, 10.1016/j.jconrel.2012.03.004 · DOI
  82. Lautenschlager, 2013, PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease, Eur J Pharm Biopharm, 85, 578, 10.1016/j.ejpb.2013.09.016 · DOI
  83. Gradauer, 2013, Liposomes coated with thiolated chitosan enhance oral peptide delivery to rats, J Control Release, 172, 872, 10.1016/j.jconrel.2013.10.011 · DOI
  84. Manconi, 2013, Improving oral bioavailability and pharmacokinetics of liposomal metformin by glycerolphosphate–chitosan microcomplexation, AAPS PharmSciTech, 14, 485, 10.1208/s12249-013-9926-4 · DOI
  85. Takeuchi, 2003, Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats, J Control Release, 86, 235, 10.1016/S0168-3659(02)00411-X · DOI
  86. Gradauer, 2012, Chemical coupling of thiolated chitosan to preformed liposomes improves mucoadhesive properties, Int J Nanomedicine, 7, 2523
  87. Thirawong, 2008, Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin–liposome nanocomplexes, J Control Release, 125, 236, 10.1016/j.jconrel.2007.10.023 · DOI
  88. Tirosh, 2009, Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa, Mol Pharm, 6, 1083, 10.1021/mp9000926 · DOI
  89. Carlson, 1999, Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion, Am J Gastroenterol, 94, 1876, 10.1111/j.1572-0241.1999.01223.x · DOI
  90. Peterson, 2002, A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease, Am J Gastroenterol, 97, 1755, 10.1111/j.1572-0241.2002.05837.x · DOI · Paper page
  91. Lamprecht, 2001, Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease, J Pharmacol Exp Ther, 299, 775, 10.1016/S0022-3565(24)29290-9 · DOI
  92. Jubeh, 2004, Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes, Pharm Res, 21, 447, 10.1023/B:PHAM.0000019298.29561.cd · DOI · Paper page
  93. Muchow, 2008, Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery, Drug Dev Ind Pharm, 34, 1394, 10.1080/03639040802130061 · DOI
  94. Beloqui, 2014, Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution, J Microencapsul, 31, 1, 10.3109/02652048.2013.788090 · DOI
  95. Meissner, 2006, Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery, Int J Pharm, 316, 138, 10.1016/j.ijpharm.2006.01.032 · DOI
  96. Cu, 2008, Controlled surface modification with poly(ethylene) glycol enhances diffusion of PLGA nanoparticles in human cervical mucus, Mol Pharm, 6, 173, 10.1021/mp8001254 · DOI
  97. Lai, 2009, Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues, Adv Drug Deliv Rev, 61, 158, 10.1016/j.addr.2008.11.002 · DOI
  98. Vong, 2012, An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice, Gastroenterology, 143, 1027, 10.1053/j.gastro.2012.06.043 · DOI
  99. Ju, 2009, A gamma-tocopherol-rich mixture of tocopherols inhibits colon inflammation and carcinogenesis in azoxymethane and dextran sulfate sodium-treated mice, Cancer Prev Res (Phila), 2, 143, 10.1158/1940-6207.CAPR-08-0099 · DOI
  100. Jin, 2008, American ginseng suppresses inflammation and DNA damage associated with mouse colitis, Carcinogenesis, 29, 2351, 10.1093/carcin/bgn211 · DOI
  101. Kotakadi, 2008, Ginkgo biloba extract EGb 761 has anti-inflammatory properties and ameliorates colitis in mice by driving effector T cell apoptosis, Carcinogenesis, 29, 1799, 10.1093/carcin/bgn143 · DOI
  102. Tobio, 2000, The role of PEG on the stability in digestive fluids and in vivo fate of PEG–PLA nanoparticles following oral administration, Colloids Surf B: Biointerfaces, 18, 315, 10.1016/S0927-7765(99)00157-5 · DOI
  103. Ashford, 1993, An in vivo investigation into the suitability of pH dependent polymers for colonic targeting, Int J Pharm, 95, 193, 10.1016/0378-5173(93)90406-6 · DOI
  104. Karn, 2011, Mucoadhesive liposomal delivery systems: the choice of coating material, Drug Dev Ind Pharm, 37, 482, 10.3109/03639045.2010.523425 · DOI
  105. Haznedar, 2004, Preparation and in vitro evaluation of Eudragit microspheres containing acetazolamide, Int J Pharm, 269, 131, 10.1016/j.ijpharm.2003.09.015 · DOI
  106. Barea, 2012, Encapsulation of liposomes within pH responsive microspheres for oral colonic drug delivery, Int J Biomater, 1, 10.1155/2012/458712 · DOI
  107. Barea, 2010, Evaluation of liposomes coated with a pH responsive polymer, Int J Pharm, 402, 89, 10.1016/j.ijpharm.2010.09.028 · DOI
  108. Makhlof, 2009, pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model, Eur J Pharm Biopharm, 72, 1, 10.1016/j.ejpb.2008.12.013 · DOI
  109. Kshirsagar, 2012, Preparation and characterization of nanocapsules for colon-targeted drug delivery system, Pharm Dev Technol, 17, 607, 10.3109/10837450.2011.557732 · DOI
  110. Legrand, 1999, Polymeric nanocapsules as drug delivery systems, STP Pharm Sci, 9, 411
  111. Ali, 2014, Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases, J Control Release, 183, 167, 10.1016/j.jconrel.2014.03.039 · DOI
  112. Beloqui, 2014, pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease, Int J Pharm, 473, 203, 10.1016/j.ijpharm.2014.07.009 · DOI
  113. Lamprecht, 2005, A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles, J Control Release, 104, 337, 10.1016/j.jconrel.2005.02.011 · DOI
  114. Laroui, 2014, Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles, Mol Ther, 22, 69, 10.1038/mt.2013.214 · DOI
  115. Xiao, 2014, Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice, Gastroenterology, 146, 1289, 10.1053/j.gastro.2014.01.056 · DOI
  116. Kriegel, 2011, Oral TNF-alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease, J Control Release, 150, 77, 10.1016/j.jconrel.2010.10.002 · DOI
  117. Kriegel, 2011, Dual TNF-alpha/cyclin D1 gene silencing with an oral polymeric microparticle system as a novel strategy for the treatment of inflammatory bowel disease, Clin Transl Gastroenterol, 2, e2, 10.1038/ctg.2011.1 · DOI
  118. Bhavsar, 2007, Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS), J Control Release, 119, 339, 10.1016/j.jconrel.2007.03.006 · DOI
  119. Moulari, 2008, The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis, Biomaterials, 29, 4554, 10.1016/j.biomaterials.2008.08.009 · DOI
  120. Li, 2004, Fabrication of porous hollow silica nanoparticles and their applications in drug release control, J Control Release, 98, 245, 10.1016/j.jconrel.2004.04.019 · DOI
  121. Simmonds, 1992, Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease, Gastroenterology, 103, 186, 10.1016/0016-5085(92)91112-H · DOI
  122. Mahida, 1989, Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease, Gut, 30, 1362, 10.1136/gut.30.10.1362 · DOI
  123. Wilson, 2010, Orally delivered thioketal nanoparticles loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines, Nat Mater, 9, 923, 10.1038/nmat2859 · DOI
  124. Leirdal, 2002, Gene silencing in mammalian cells by preformed small RNA duplexes, Biochem Biophys Res Commun, 295, 744, 10.1016/S0006-291X(02)00736-2 · DOI
  125. Zhang, 2007, Cationic lipids and polymers mediated vectors for delivery of siRNA, J Control Release, 123, 1, 10.1016/j.jconrel.2007.07.016 · DOI
  126. Thiele, 2001, Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages?, J Control Release, 76, 59, 10.1016/S0168-3659(01)00412-6 · DOI
  127. Hua, 2013, Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies, Front Pharmacol, 4, 127, 10.3389/fphar.2013.00127 · DOI
  128. Sofou, 2008, Antibody-targeted liposomes in cancer therapy and imaging, Expert Opin Drug Deliv, 5, 189, 10.1517/17425247.5.2.189 · DOI
  129. Willis, 1998, Ligand-targeted liposomes, Adv Drug Deliv Rev, 29, 249, 10.1016/S0169-409X(97)00083-5 · DOI
  130. Saltzman, 1994, Antibody diffusion in human cervical mucus, Biophys J, 66, 508, 10.1016/S0006-3495(94)80802-1 · DOI
  131. Mane, 2012, Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice, Int J Nanomedicine, 7, 4223
  132. Sans, 1999, VCAM-1 and ICAM-1 mediate leukocyte–endothelial cell adhesion in rat experimental colitis, Gastroenterology, 116, 874, 10.1016/S0016-5085(99)70070-3 · DOI
  133. Danese, 2005, Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation, Dig Liver Dis, 37, 811, 10.1016/j.dld.2005.03.013 · DOI
  134. Binion, 1998, Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease, Lancet, 352, 1742, 10.1016/S0140-6736(98)05050-8 · DOI
  135. Binion, 1997, Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease, Gastroenterology, 112, 1895, 10.1053/gast.1997.v112.pm9178682 · DOI
  136. Bernstein, 1996, Beta 2-integrin/intercellular adhesion molecule (ICAM) expression in the normal human intestine, Clin Exp Immunol, 106, 160
  137. Salmi, 1994, Aberrant binding of lamina propria lymphocytes to vascular endothelium in inflammatory bowel diseases, Gastroenterology, 106, 596, 10.1016/0016-5085(94)90691-2 · DOI
  138. Wileman, 1986, Identification of the macrophage mannose receptor as a 175-kDa membrane protein, Proc Natl Acad Sci U S A, 83, 2501, 10.1073/pnas.83.8.2501 · DOI
  139. van Vliet, 2008, Sweet preferences of MGL: carbohydrate specificity and function, Trends Immunol, 29, 83, 10.1016/j.it.2007.10.010 · DOI
  140. Xiao, 2013, Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-alpha RNA interference for IBD therapy, Biomaterials, 34, 7471, 10.1016/j.biomaterials.2013.06.008 · DOI
  141. Zhang, 2013, Galactosylated trimethyl chitosan–cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages, Biomaterials, 34, 3667, 10.1016/j.biomaterials.2013.01.079 · DOI
  142. Laroui, 2014, Fab′-bearing siRNA TNFalpha-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis, J Control Release, 186, 41, 10.1016/j.jconrel.2014.04.046 · DOI
  143. Harel, 2011, Enhanced transferrin receptor expression by proinflammatory cytokines in enterocytes as a means for local delivery of drugs to inflamed gut mucosa, PLoS One, 6, e24202, 10.1371/journal.pone.0024202 · DOI
  144. Xiao, 2014, Glycoprotein CD98 as a receptor for colitis-targeted delivery of nanoparticle, J Mater Chem B Mater Biol Med, 2, 1499, 10.1039/c3tb21564d · DOI
  145. Kucharzik, 2005, Activation of epithelial CD98 glycoprotein perpetuates colonic inflammation, Lab Invest, 85, 932, 10.1038/labinvest.3700289 · DOI
  146. Nguyen, 2012, Homeostatic and innate immune responses: role of the transmembrane glycoprotein CD98, Cell Mol Life Sci, 69, 3015, 10.1007/s00018-012-0963-z · DOI

Cited by

Sorted by citations

See all 494

Metadata

Authors
Hua, S., Marks, E., Schneider, J. J., & Keely, S.
Venue
Nanomedicine: Nanotechnology, Biology and Medicine
Publisher
Elsevier BV
Published
2015-07
Volume
11
Issue
5
Pages
1117-1132
ISSN
1549-9634
DOI
10.1016/j.nano.2015.02.018
Cited by
494
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review